Harmony Biosciences Holdings Inc Earnings

Harmony Biosciences Holdings Inc’s revenue jumped 19.48% since last year same period to $184.73Mn in the Q1 2025. On a quarterly growth basis, Harmony Biosciences Holdings Inc has generated -8.21% fall in its revenue since last 3-months.

Harmony Biosciences Holdings Inc’s net profit jumped 18.85% since last year same period to $45.56Mn in the Q1 2025. On a quarterly growth basis, Harmony Biosciences Holdings Inc has generated -7.91% fall in its net profits since last 3-months.

Harmony Biosciences Holdings Inc’s net profit margin fell -0.53% since last year same period to 24.66% in the Q1 2025. On a quarterly growth basis, Harmony Biosciences Holdings Inc has generated 0.33% jump in its net profit margins since last 3-months.

Harmony Biosciences Holdings Inc’s price-to-earnings ratio after this Q1 2025 earnings stands at 12.4.

Harmony Biosciences Holdings Inc’s earning per share (EPS) estimates for the current quarter stand at 0.91 - a 11.81% jump from last quarter’s estimates.

Harmony Biosciences Holdings Inc’s earning per share (EPS) estimates for the current year stand at 0.91.

Harmony Biosciences Holdings Inc’s earning per share (EPS) jumped 16.19% since last year same period to 0.78 in the Q1 2025. This indicates that the Harmony Biosciences Holdings Inc has generated 16.19% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Harmony Biosciences Holdings Inc’s return on assets (ROA) stands at 0.13.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Harmony Biosciences Holdings Inc’s return on equity (ROE) stands at 0.25.